Table 3.

Incidence of ADA-positive assay responses during TEAE period

Anti-sarilumab antibody, n (%)	Sarilumab
	150 mg q2w (n = 65)	200 mg q2w (n = 66)
ADA-negative patients	49 (75.4)	54 (81.8)
Pre-existing ADA	1 (1.5)	2 (3.0)
Treatment-emergent ADA	16 (24.6)	12 (18.2)
Median peak titer (min–max)	30 (30–240)	30 (30–120)
Transient positive response	8 (12.3)	8 (12.1)
Persistent positive response	8 (12.3)	4 (6.1)
Neutralizing	7 (10.8)	2 (3.0)
Non-neutralizing	1 (1.5)	2 (3.0)

ADA antidrug antibody, q2w every 2 weeks, TEAE treatment-emergent adverse event